MetaCap

Immuron (IMRN) vs Vistagen Therapeutics (VTGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vistagen Therapeutics is the larger company by market cap ($7.6 million vs $7.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMRN-17.45%VTGN-33.79%
+4%-16%-36%
Oct 7, 20261 yearNov 20, 2026
IMRN-16.69%VTGN-30.71%
+2%-15%-32%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMRN versus VTGN key metrics
MetricIMRNVTGN
Share price$0.8998$0.1636
Market cap$7.26M$7.56M
1-day change+5.80%-12.33%
YTD return—-75.21%
1-year return—-96.44%
5-year return—-99.72%
EPS (TTM)$-0.34$-1.36
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.27M
Revenue growth (YoY)—+161.11%
Net income (latest FY)—$-69.69M
Operating margin—-5683.69%
Net margin—-5491.33%
52-week high$1.99$5.14
52-week low$0.677$0.16
Distance from 52-week high-54.78%-96.82%
Analyst consensusnonenone
Avg. price target upside+332.32%+511.25%
Average volume2.06M10.30M
Shares outstanding8.07M46.19M
Employees741
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Immuron

IMRN stock →

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Vistagen Therapeutics

VTGN stock →

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder.

Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees

IMRN vs VTGN FAQ

Which is bigger, Immuron or Vistagen Therapeutics?

Vistagen Therapeutics (VTGN) is larger, with a market capitalization of $7.56M compared with $7.26M for Immuron (IMRN).

Are Immuron and Vistagen Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons